BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript

Core Insights - The company announced positive Phase III data from the CALIBRATE clinical trial for patients with autosomal dominant hypocalcemia type 1, marking a significant advancement for ADH1 patients [2][3]. Group 1 - The webinar was hosted by the company to present the top line results of the CALIBRATE Phase III trial [1]. - The CEO expressed gratitude towards the team and stakeholders involved in the trial, highlighting the importance of the results for patients and their families [2].